Study Title

A Phase 1/2, Open-label Study to Assess Safety, Tolerability, Biodistribution, Radiation Dosimetry and PET Imaging Characteristics of [18F]FPyGal in Comparison to in Vitro Diagnostics for the Assessment of Senescence in Oncological Patients

Study Details

Description:

It is of particular interest to find out whether it is possible to use the novel radiotracer [18F]FPyGal to be tested to detect areas after standard tumor therapy that contain resistant (therapy-resistant) tumor cells. This resistance phenomenon in tumor tissues, which may be visualized with the radiotracer [18F]FPyGal, is called tumor senescence.

Sponsor:

University Hospital Tuebingen

Contacts:

Christian la Fougere, MD

christian.lafougere@med.uni-tuebingen.de

+49-7071 29-0

Ulrich M Lauer, MD

ulrich.lauer@med.uni-tuebingen.de

+49-7071 29-0

Government Study Link:

NCT04536454 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468